Kiniksa Pharmaceuticals International (KNSA) Change in Account Payables (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Change in Account Payables for 10 years, with the latest figure at $22.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables rose 35812.9% year-over-year to $22.3 million; the trailing twelve-month figure through Mar 2026 stood at $22.3 million (up 723.84% YoY), and the FY2025 full-year result was $142000.0, up 102.25% from the prior year.
• Change in Account Payables for Q1 2026 stood at $22.3 million, up from -$4.1 million in the prior quarter.
• The five-year high for Change in Account Payables was $22.3 million in Q1 2026, with the low at -$6.5 million in Q1 2023.
• Historically, Change in Account Payables has averaged $1.3 million across 5 years, with a median of $62000.0 in 2025.
• Annual changes were most pronounced in 2023 — Change in Account Payables slumped 529.57% — and 2026, when it jumped 35812.9%.
• Kiniksa Pharmaceuticals International's Change in Account Payables stood at $6.4 million in 2022, then increased by 12.5% to $7.2 million in 2023, then sank by 186.87% to -$6.3 million in 2024, then jumped by 34.4% to -$4.1 million in 2025, then jumped by 640.17% to $22.3 million in 2026.
• The last three Change in Account Payables figures came in at $22.3 million (Q1 2026), -$4.1 million (Q4 2025), and -$2.7 million (Q3 2025), per Business Quant data.